Novartis Ag

Seth Alexander Ettenberg

Nicole Haubst

Feng Cong

Winfried Elis

Andrew Paul Garner

Elizabeth Anne Reisinger Sprague

David Jenkins

Stefanie Urlinger

Michael Otto Bardroff

Christian Kunz

Tiancen Hu

Mark C Fishman

Xizhong Huang

Matthew John Meyer

Christian Carsten Silvester Kunz

Konstantin Petropoulos

Engin Toksoz

Qing Sheng

David Bryant Batt

Janine R Shulok

Mariel Donzeau

Ming Lei

Andreas Loew

Bruno Dombrecht

Joost Alexander Kolkman

Jing Li

Karen Cromie

Li Zhou

Karen Vincent

Ingo Klagge

David Raymond Stover

Felix Hartlepp

Kris Meerschaert

Jingxin Zhang

This invention relates to antibodies or fragments thereof which interact with HER family of receptors, e.g., HER3 receptor. In particular, it relates to antibodies or fragments thereof that recognize a conformational epitope of HER3 receptor comprising residues from both domains 2 and 4 resulting in inhibition of both ligand-dependent and ligand-independent signal transduction; and allow ligand binding (e.g., neuregulin), while preventing ligand-induced activation of signal transduction. These antibodies or fragments can be used to treat a number of diseases or disorders characterized by increased levels of HER3 expression (e.g., esophageal cancer). These antibodies or fragments can be used to treat a number of diseases or disorders characterized by the antibodys or fragments ability to decrease tissue weight (e.g., prostate or uterine weights) or to induce atrophy of tissue (e.g., atrophy of male breast).

Antibodies for epidermal growth factor receptor 3 (HER3)

The present invention relates to antibodies or fragments thereof that target a conformational epitope of a HER receptor. In particular, the invention relates to antibodies or fragments thereof that target a conformational epitope of HER3 receptor and compositions and methods of use thereof.

The present invention relates to anti-FGFR2 and FGFR4 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.

Antibody drug conjugates

The present disclosure relates to antibodies targeting LRPand compositions and methods of use thereof.

Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies

The present invention relates to anti-FGFR2 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.

Antibodies and fragments that bind to the protein target Dickkopf (DKK1) are provided, as are methods of use and kits, for treating a target cell, in particular, a cell associated with an osteolytic condition.

Compositions and methods of use for antibodies of Dickkopf-1

The present disclosure relates to an antibody or antigen binding fragment having at least two receptor binding domains for two different binding sites of LRP6 and compositions and methods of use thereof.

Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies

The present invention relates to amino acid sequences that are directed against TRAIL cell surface receptor 2 (herein also 'DR5'), as well as to compounds or constructs thereof, and in particular proteins and polypeptides and nucleotides that encode them (referred to herein in their entirety as 'NB agents') and fragments thereof, and pharmaceutically effective variants thereof, and their use in the diagnosis and treatment of DR5 associated diseases and disorders.

Biologic compounds directed against death receptor 5

Compositions and methods of use for antibodies of dickkopf-1

Growing community of inventors

Cambridge, MA, United States of America

Seth Alexander Ettenberg